Reasons for interindividual variation in steady-state serum phosphorus concentrations are largely unknown.

These associations may explain the link between serum phosphorus levels and CVD events.

In addition, the patient had low to low-normal serum phosphorus with high urine phosphorus.

The high phosphate diet did not affect serum phosphorus concentration.

The calcimimetic cinacalcet reduces both serum calcium and PTH levels and raises serum phosphorus.

Factors determining serum phosphorus concentration are largely unknown.

A higher serum phosphorus level is associated with cardiovascular disease (CVD) events among community-living populations.

However, regardless of the dietary phosphate contents, serum phosphorus levels were consistently elevated in Galnt3 knockout mice.

There was no statistically significant association between urine DA, serum phosphorus, FGF-23 or PTH in adjusted models.

The total amount of phosphate binders prescribed was adjusted to maintain the serum phosphorus at normal levels.

Intact FGF23 correlated with serum phosphorus.

The Ca x PO4 product, however, showed a mortality risk trend similar to that seen with serum phosphorus alone.

Logistic regression analysis is then used to describe the demographic, comorbid, and laboratory parameters associated with high serum phosphorus.

Dietary intakes of phosphorus and phosphorus-rich foods were associated only weakly with circulating serum phosphorus concentrations, if at all.

On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population.

Background: Phosphate binders are widely used to control serum phosphorus levels in patients with chronic kidney disease (CKD).